You are here

stem cells

Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO

Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO

Business Insider

wrinkle treatment

Flag link:

Cellect, denovoMATRIX start stem cell research project

Cellect, denovoMATRIX start stem cell research project

Fierce Biotech

Cellect Biotechnology

drug development

Flag link:

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

Xconomy

sickle cell disease

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies

Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies

Fierce Biotech

type 1 diabetes

Flag link:

Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations

Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations

Endpoints

type 1 diabetes

Flag link:

Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis

Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis

CP Wire

Cellular Biomedicine

osteoarthritis of the knee

Flag link:

Amgen bets on stem cell company Fortuna Fix in $25M round

Amgen bets on stem cell company Fortuna Fix in $25M round

Endpoints

Flag link:

A Change in Direction on Stem Cell Policy? It’s About Time

A Change in Direction on Stem Cell Policy? It’s About Time

FDA Law Blog

Flag link:

CSL snags a preclinical stem cell therapy in $416M Calimmune buyout

CSL snags a preclinical stem cell therapy in $416M Calimmune buyout

Endpoints

Flag link:

J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it

J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it

Endpoints

Flag link:

New Texas Law on Stem Cell Treatments: Showdown With FDA Coming?

New Texas Law on Stem Cell Treatments: Showdown With FDA Coming?

RAPS.org

Flag link:

Athersys And Aurinia Target Human And Animal Health

Athersys And Aurinia Target Human And Animal Health

Seeking Alpha

Aurinia Pharmaceuticals

Flag link:

Texas on track to become first state to explicitly back stem cell therapies

Texas on track to become first state to explicitly back stem cell therapies

Stat

Flag link:

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

Endpoints

Magenta Therapeutics

Flag link:

How AbbVie Is Attacking Tumors at Their Roots

How AbbVie Is Attacking Tumors at Their Roots

Motley Fool

Flag link:

Three patients blinded by stem cell procedure, physicians say

Three patients blinded by stem cell procedure, physicians say

Stat

clinical trials

macular degeneration

Flag link:

9 cardiology breakthroughs you need to know

9 cardiology breakthroughs you need to know

Mass Device

robotic heart sleeve

aortic stenosis

Flag link:

Takeda, TiGenix stem cell therapy shows sustained effect

Takeda, TiGenix stem cell therapy shows sustained effect

Fierce Biotech

Crohn's Disease

Flag link:

Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment

Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment

Mass Device

Flag link:

STAT’s stats of the year: 2016 by the numbers

STAT’s stats of the year: 2016 by the numbers

Stat

venture capital

Flag link:

Pages